A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus
NCT07662109
This study is recruiting at 17 US sites in 14 states, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability of elecoglipron and dapagliflozin in combination, compared with elecoglipron alone and dapagliflozin alone, in adults with type 2 diabetes mellitus (T2DM) inadequately managed with lifestyle management alone or treated with other background glucose-lowering medication.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Type 2 Diabetes Mellitus
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- AstraZeneca
- Last updated on ClinicalTrials.gov
- October 30, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 1
- Research Site · Little Rock, AR
California · 1
- Research Site · Los Angeles, CA
Florida · 2
- Research Site · Lake City, FL
- Research Site · Lakeland, FL
Illinois · 1
- Research Site · Chicago, IL
Maryland · 1
- Research Site · Oxon Hill, MD
Michigan · 1
- Research Site · Troy, MI
Mississippi · 1
- Research Site · Ridgeland, MS
New Mexico · 1
- Research Site · Albuquerque, NM
New York · 1
- Research Site · Brooklyn, NY
Ohio · 1
- Research Site · Maumee, OH
Tennessee · 2
- Research Site · Kingsport, TN
- Research Site · Nashville, TN
Texas · 2
- Research Site · Dallas, TX
- Research Site · Paris, TX
Virginia · 1
- Research Site · Newport News, VA
West Virginia · 1
- Research Site · Kingwood, WV
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.